Glenmark Pharmaceuticals Inc. has been granted final approval by the US FDA for Triamcinolone Acetonide Ointment USP, the generic version of Kenalog Ointment, 0.1 percent, of Mylan Pharmaceuticals.

According to IMS Health, sales data for the 12 month period ending June 2017, the Kenalog Ointment market achieved annual sales of USD 26.3 million.

Glenmark's current portfolio consists of 122 products authorized for distribution in the US marketplace and 64 ANDA's pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

10 Diagnostic Imaging Trends for 2018


Digital version